Palbociclib CAS 571190-30-2 Ịdị Ọcha> 99.5% (HPLC) Ụlọ ọrụ API
Ruifu Chemical Supply Palbociclib metụtara Intermediates:
Palbociclib CAS 571190-30-2
5-Bromo-2,4-Dichloropyrimidine CAS 36082-50-5
5-Bromo-2-Chloro-N-Cyclopentylpyrimidin-4-Amine CAS 733039-20-8
tert-Butyl 4-(6-Nitropyridin-3-yl)piperazine-1-Carboxylate CAS 571189-16-7
tert-Butyl 4-(6-Amino-3-Pyridyl)piperazine-1-Carboxylate CAS 571188-59-5
6-Bromo-2-Chloro-8-Cyclopentyl-5-Methylpyrido-[2,3-d]pyrimidin-7(8H) -otu CAS 1016636-76-2
2-Chloro-8-Cyclopentyl-5-Methyl-8H-Pyrido[2,3-d]pyrimidin-7-otu CAS 1013916-37-4
Aha Chemical | Palbociclib |
Ụdị okwu | PD-0332991;Otava-Bb 1115529;Ibrance |
Nọmba CAS | 571190-30-2 |
Ọnọdụ Ahịa | N'ọkwa, Mpụta Ihe ruru Tọn |
Usoro ihe omimi | C24H29N7O2 |
Ibu molekụla | 447.54 |
Ụdị | Ruifu Chemical |
Ihe | Nkọwapụta |
Ọdịdị | Ọcha ma ọ bụ Gbanyụọ-Ọcha ntụ ntụ |
1H NMR Spectrum | Nkwekọrịta na Ọdịdị |
HPLC | Nkwekọrịta na Ọdịdị |
Ihe ndị emetụtara | |
Ọdịghị ọcha nke Onwe Onye | <0.50% |
Mgbakọta adịghị ọcha | <1.00% |
Ọnwụ na ihicha | <0.50% |
Ihe fọdụrụ na mgbanye | <0.10% |
Ọla dị arọ | <10ppm |
Ụzọ ịdị ọcha / nyocha | > 99.5% (HPLC) |
Nlele ọkọlọtọ | Standardkpụrụ ụlọ ọrụ |
Ojiji | API, Na Ọgwụgwọ Ọrịa Cancer |
ngwugwu: Kalama, Aluminom foil bag, 25kg / Cardboard Drum, ma ọ bụ dị ka ndị ahịa chọrọ
Ọnọdụ Nchekwa:Na-echekwa n'ime akpa ndị a kpuchiri ekpuchi na ebe dị jụụ na nke kpọrọ nkụ;Chebe site na ìhè na mmiri mmiri
Palbociclib (CAS: 571190-30-2) bụ onye na-egbochi cyclin-dependent kinase (CDK) nke nwere ike ịrụ ọrụ antineoplastic.Palbociclib na-ahọrọ nke ọma na-egbochi cyclin-based kinase 4 (CDK4) na 6 (CDK6), si otú a na-egbochi retinoblastoma (Rb) protein phosphorylation n'isi mmalite nke G1 na-eduga na njide okirikiri cell.Nke a na-egbochi mmeghari DNA ma na-ebelata mmụba cell tumor.Palbociclib bụ onye nnọchi anya mbụ nke klas ọgwụ ọhụrụ nke inhibitors kinase inhibitors cyclin.Mmetụta a na-egbochi mmụba cell (mkpụrụ ndụ na nkewa).A na-eji ya dị ka onye na-ahụ maka antineoplastic na ọrịa cancer ara dị elu ma ọ bụ metastatic.